Terpenolol is a newly developed hydrophilic derivative of cannabidiol (CBD) designed to overcome the solubility, stability, and pharmacokinetic limitations of conventional lipophilic CBD formulations. This study presents its physicochemical profile, 30‑day stability, and preliminary pharmacokinetic behavior in humans. Terpenolol forms a stable aqueous micellar‑like dispersion with neutral pH (7.0 ± 0.1), consistent viscosity, and minimal variation in tintometric and colloidal parameters over the observation period.In a single‑dose, two‑period crossover study involving five healthy volunteers, sublingual administration of Terpenolol resulted in markedly higher plasma CBD concentrations at 30 minutes compared with an oil‑based reference formulation. Observational data from more than 200 individuals using Terpenolol‑based preparations across oral, nasal, cutaneous, and transdermal routes indicate good tolerability and reported improvements in anxiety, panic symptoms, insomnia, psychotic‑spectrum disturbances, and musculoskeletal or joint pain.The compound’s complete solubility in aqueous media, combined with its neutral taste and odorless profile, also supports its incorporation into functional beverages, as demonstrated by a prototype mineral water formulation containing 50 mg of CBD in 500 ml.Overall, Terpenolol demonstrates physicochemical stability, improved early systemic exposure to CBD, and broad formulation compatibility. Controlled studies are planned to further define its pharmacological relevance and potential application domains.
This communication explores the transition from Cognitive Behavioural Therapy (CBT) to a more holistic model, named Complex Therapy, developed by Tullio Scrimali for explaining and treating mental disorders. The Author delves into the limitations of traditional CBT and introduces an innovative framework that integrates multiple therapeutic modalities. While CBT is based on the study and modification of behaviour and cognition, Complex Therapy includes, in its focus, the theory of human relationships, the attachment theory, neuroscience, applied neuroscience, complex systems theory and ecology.Complex Therapy addresses the multifaceted nature of mental health issues by combining evidence-based techniques with personalized care strategies. The goal is to enhance patient outcomes through a tailored, comprehensive treatment plan that adapts to the evolving needs of individuals facing mental health challenges.Two innovative and original items which Scrimali has developed, which are a device for Applied Neuroscience MindLAB Set and a new botanical drug, NegEnt, are presented and discussed.The topic also describes, an original and integrated protocol, named Negative Entropy, the author has developed for treating a challenging disorder, such as schizophrenia, he renamed Entropy of Mind.
Musculoskeletal disorders are a common occurrence in Europe, affecting millions of people and costing billions of euros in social security services. Traditional treatments using drugs like non-steroidal anti-inflammatory drugs (NSAIDs) can cause gastric damage, making prolonged use difficult. To address this issue, the Author has developed NegEnt Spray - Muscles and Joints, a topical medical device that uses liposomal cannabidiol and chamomile hydrolate to reduce inflammation and pain in musculoskeletal disorders. The liposomal technology used in NegEnt Spray allows for better bioavailability and a more targeted action, while chamomile hydrolate provides a natural anti-inflammatory and soothing effect. The spray is non-greasy, absorbs quickly, and can be used under any circumstances. Its pocket-sized design makes it easy to carry and use throughout the day. With NegEnt Spray, patients can alleviate discomfort and pain associated with musculoskeletal disorders without worrying about the side effects of traditional treatments.
Terpenolol is an engineered, high- shear dispersed aqueous formulation containing cannabidiol (CBD), medium- chain triglycerides (MCT), sunflower- seed lecithin, and purified water, produced via controlled high- energy, high- shear mechanical processing. The formulation was previously described as a nanomicellar, hydrophilic CBD -derived system (Scrimali, 2026c). The present article integrates published membrane- biophysics and ion- channel evidence with Terpenolol- specific human electrodermal observations to evaluate the hypothesis that biophysical membrane modulation represents a central mechanistic component of Terpenolol neuromodulation. The contemporary literature establishes that CBD partitions into lipid bilayers, modifies membrane physical properties, and modulates voltage- gated sodium channels (Nav) through mechanisms that encompass both direct protein interactions and a parallel, bilayer- mediated component. Separately, primary bilayer studies demonstrate that alterations in bilayer elasticity can regulate sodium- channel inactivation and use- dependent current behavior. Preliminary analysis of completed, Terpenolol- specific unpublished observations suggests a baseline- dependent electrodermal pattern, with a reduction when initial autonomic activation is elevated and substantially smaller change within physiological baseline conditions. These findings do not exclude CBD polypharmacology or direct channel binding. Rather, they support a convergent model in which membrane- mediated modulation constitutes one central component of the formulation’s neuromodulatory action. Two focused studies are proposed to consolidate the formulation-specific chain: external physicochemical characterization of Terpenolol and targeted in vitro biophysical testing using an appropriate heterologous cellular system, a defined synthetic lipid-bilayer model, or both, to distinguish formulation-specific membrane effects from direct CBD–protein interactions.
The article presents the potential of liposomal cannabidiol in the treatment of Panic Disorder, when used in integration with Complex Cognitive Psychotherapy. The advantages of the integrated treatment, developed by the Author, and based on the use of liposomal cannabidiol combined with cognitive psychotherapy, are discussed. A new and original tool is presented and described, developed, and tested for the first time by the Author and called NegEnt Panic Blocker.
Canine anxiety is a widespread behavioral condition that compromises animal welfare and increases the risk of stress-related behavioral dysregulation. Severe anxiety disrupts cognitive processing, sleep regulation, and social functioning, often requiring pharmacological support to enable behavioral rehabilitation. This case report describes the clinical response of a 4-year-old Italian Volpino dog with chronic anxiety, hyperarousal, and stress-related dysregulation treated with a micellar CBD formulation (NegEnt). The treatment produced rapid improvements in sleep continuity, arousal modulation, social behavior, and impulse control without cognitive or motor impairment. Furthermore, a planned temporary discontinuation demonstrated the absence of withdrawal or rebound effects, followed by sustained long-term efficacy over a two-month maintenance period. These observations suggest that micellar CBD may facilitate a "window of cognitive plasticity" that supports behavioral therapy. Controlled studies are required to confirm these preliminary findings.